Vimarsana
Biggest News Aggregation in the World

Page 17 - Resented News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Resented. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Resented Today - Breaking & Trending Today

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing - Vimarsana News

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

Biodesix, Inc. , a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR conference, providing... | May 25, 2023

3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023 - Vimarsana News

3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023

France’s Jean-Louis Pépin and Germany’s Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with... | May 25, 2023

AUGA group, AB and its subsidiaries presented to the public and investors the principles of a new business model that will enable scaling of technology and sustainable food supply - Vimarsana News

AUGA group, AB and its subsidiaries presented to the public and investors the principles of a new business model that will enable scaling of technology and sustainable food supply

AUGA group, AB presented the key principles of the new business model of the Company and its subsidiaries along with the steps for its implementation, as approved by the Company’s Board. The... | May 25, 2023

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma - Vimarsana News

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR /KEYNOTE-581 trial Final results will be presented at ASCO 2023... | May 25, 2023

Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress - Vimarsana News

Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Incyte today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting held... | May 25, 2023